JP7691421B2 - Ｇｌｐ２受容体アゴニストおよびその使用方法 - Google Patents

Ｇｌｐ２受容体アゴニストおよびその使用方法 Download PDF

Info

Publication number
JP7691421B2
JP7691421B2 JP2022531616A JP2022531616A JP7691421B2 JP 7691421 B2 JP7691421 B2 JP 7691421B2 JP 2022531616 A JP2022531616 A JP 2022531616A JP 2022531616 A JP2022531616 A JP 2022531616A JP 7691421 B2 JP7691421 B2 JP 7691421B2
Authority
JP
Japan
Prior art keywords
peptide
glp2
amino acid
glp
alkylene
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022531616A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023513658A5 (https=
JP2023513658A (ja
JPWO2021113524A5 (https=
Inventor
シェン，ウェイジュン
ジー． シュルツ，ピーター
アムソ，ザイド
Original Assignee
ザ スクリプス リサーチ インスティテュート
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ザ スクリプス リサーチ インスティテュート filed Critical ザ スクリプス リサーチ インスティテュート
Publication of JP2023513658A publication Critical patent/JP2023513658A/ja
Publication of JP2023513658A5 publication Critical patent/JP2023513658A5/ja
Publication of JPWO2021113524A5 publication Critical patent/JPWO2021113524A5/ja
Application granted granted Critical
Publication of JP7691421B2 publication Critical patent/JP7691421B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Peptides Or Proteins (AREA)
JP2022531616A 2019-12-04 2020-12-03 Ｇｌｐ２受容体アゴニストおよびその使用方法 Active JP7691421B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962943667P 2019-12-04 2019-12-04
US62/943,667 2019-12-04
US202062994791P 2020-03-25 2020-03-25
US62/994,791 2020-03-25
PCT/US2020/063130 WO2021113524A2 (en) 2019-12-04 2020-12-03 Glp2 receptor agonists and methods of use

Publications (4)

Publication Number Publication Date
JP2023513658A JP2023513658A (ja) 2023-04-03
JP2023513658A5 JP2023513658A5 (https=) 2023-12-12
JPWO2021113524A5 JPWO2021113524A5 (https=) 2023-12-12
JP7691421B2 true JP7691421B2 (ja) 2025-06-11

Family

ID=76222285

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022531616A Active JP7691421B2 (ja) 2019-12-04 2020-12-03 Ｇｌｐ２受容体アゴニストおよびその使用方法
JP2022532862A Active JP7834640B2 (ja) 2019-12-04 2020-12-03 ペプチドコンジュゲートおよび使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022532862A Active JP7834640B2 (ja) 2019-12-04 2020-12-03 ペプチドコンジュゲートおよび使用方法

Country Status (10)

Country Link
US (2) US12583900B2 (https=)
EP (2) EP4069274A4 (https=)
JP (2) JP7691421B2 (https=)
KR (2) KR20220110244A (https=)
CN (2) CN115052886B (https=)
AU (2) AU2020397917A1 (https=)
CA (2) CA3163522A1 (https=)
IL (2) IL293460A (https=)
MX (2) MX2022006861A (https=)
WO (2) WO2021113535A1 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014364589B2 (en) 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AU2020397917A1 (en) 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.
WO2023207106A1 (zh) * 2022-04-29 2023-11-02 苏州星洲生物科技有限公司 Glp-1/gip受体共激动剂、包含其的药物组合物及其用途
CN114949183B (zh) * 2022-05-07 2023-02-28 山东京卫制药有限公司 一种替尔泊肽粉雾剂及其制备方法
TW202410918A (zh) * 2022-05-27 2024-03-16 韓商Ｄ＆Ｄ製藥科技股份有限公司 用於治療神經病症之組合物及方法
CR20250247A (es) * 2022-12-21 2025-08-18 Boehringer Ingelheim Int Agonistas triples de los receptores de glp1/gip/npy2
CN117586374B (zh) * 2023-10-07 2024-11-29 深圳湾实验室 Glp-1r/gipr/gcgr三重激动剂类似物及其用途
WO2025184552A2 (en) * 2024-03-01 2025-09-04 The Scripps Research Institute Dual gip/glp-1 peptide conjugates and methods of use
WO2025217640A1 (en) * 2024-04-12 2025-10-16 Eli Lilly And Company Compositions and methods for treating metabolic diseases

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof
JP2017502024A (ja) 2013-12-18 2017-01-19 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物

Family Cites Families (125)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3887699A (en) 1969-03-24 1975-06-03 Seymour Yolles Biodegradable polymeric article for dispensing drugs
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
PH19942A (en) 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US6565841B1 (en) 1991-03-15 2003-05-20 Amgen, Inc. Pulmonary administration of granulocyte colony stimulating factor
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
WO1993015722A1 (en) 1992-02-07 1993-08-19 Syntex (Usa) Inc. Controlled delivery of pharmaceuticals from preformed porous microparticles
WO1994012158A1 (en) 1992-12-02 1994-06-09 Alkermes Controlled Therapeutics, Inc. Controlled release growth hormone containing microspheres
EP0707650B1 (en) 1993-06-21 2003-05-21 Genentech, Inc. Process for producing human relaxin
US6011007A (en) 1993-09-17 2000-01-04 Novo Nordisk A/S Acylated insulin
CZ287945B6 (cs) 1993-09-17 2001-03-14 Novo Nordisk A/S Inzulinový derivát a farmaceutický prostředek s jeho obsahem pro léčení diabetu
US6869930B1 (en) 1993-09-17 2005-03-22 Novo Nordisk A/S Acylated insulin
US6372716B1 (en) 1994-04-26 2002-04-16 Genetics Institute, Inc. Formulations for factor IX
DK0779806T3 (da) 1994-09-09 2000-11-27 Takeda Chemical Industries Ltd Præparat til forsinket frigivelse indeholdende et metalsalt af et peptid
ATE212545T1 (de) 1995-03-28 2002-02-15 Fidia Advanced Biopolymers Srl Nanosphären mit einem biokompatiblen polysaccharid
US6184201B1 (en) 1995-04-14 2001-02-06 Nps Allelix Corp. Intestinotrophic glucagon-like peptide-2 analogs
TW457240B (en) 1995-04-20 2001-10-01 Janssen Pharmaceutica Nv Novel triazolones as apolipoprotein-B synthesis inhibitors
US5811395A (en) 1995-06-07 1998-09-22 Medical University Of South Carolina Relaxin analogs and derivatives methods and uses thereof
NZ310644A (en) 1995-06-07 1999-08-30 Alkermes Inc Composition for sustained release of human growth hormone
US5911997A (en) 1995-06-07 1999-06-15 Connetics Corporation Relaxin-like factor and methods and uses thereof
ZA965368B (en) 1995-07-14 1997-01-14 Novo Nordisk As A pharmaceutical formulation
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5612051A (en) 1995-11-17 1997-03-18 Yue; Samuel K. Method of treating involuntary muscle dysfunction with relaxin hormone
US5866538A (en) 1996-06-20 1999-02-02 Novo Nordisk A/S Insulin preparations containing NaCl
US6268343B1 (en) 1996-08-30 2001-07-31 Novo Nordisk A/S Derivatives of GLP-1 analogs
US6444641B1 (en) 1997-10-24 2002-09-03 Eli Lilly Company Fatty acid-acylated insulin analogs
ZA989744B (en) 1997-10-31 2000-04-26 Lilly Co Eli Method for administering acylated insulin.
DE19822820A1 (de) 1998-05-20 1999-11-25 Biotechnolog Forschung Gmbh Pharmazeutisches Präparat zur Wundbehandlung
US6566329B1 (en) 1999-06-28 2003-05-20 Novo Nordisk A/S Freeze-dried preparation of human growth hormone
JP2004535401A (ja) 2001-05-21 2004-11-25 ネクター セラピューティックス 化学的に改変されたインスリンの肺投与
EP1572720A4 (en) 2002-05-24 2008-12-24 Nps Allelix Corp PROCESS FOR THE ENZYMATIC PRODUCTION OF GLP-2 (1-34) AND GLP-2 (1-33) PEPTIDES
AU2003239478A1 (en) * 2002-06-04 2003-12-22 Eli Lilly And Company Modified glucagon-like peptide-1 analogs
US20050176108A1 (en) 2003-03-13 2005-08-11 Young-Min Kim Physiologically active polypeptide conjugate having prolonged in vivo half-life
WO2004100997A2 (en) 2003-05-12 2004-11-25 Affymax, Inc. Spacer moiety for poly(ethylene glycol) -modified peptides
US20060183667A1 (en) 2003-07-11 2006-08-17 Novo Nordisk A/S Stabilised insulin compositions
KR101241862B1 (ko) 2003-09-19 2013-03-13 노보 노르디스크 에이/에스 신규 ｇｌｐ-1 유도체
WO2005118620A2 (en) 2004-05-27 2005-12-15 New York University Methods for preparing internally constraied peptides and peptidomimetics
WO2006066258A2 (en) 2004-12-17 2006-06-22 Neose Technologies, Inc. Lipoconjugation of peptides
TWI372629B (en) 2005-03-18 2012-09-21 Novo Nordisk As Acylated glp-1 compounds
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
WO2007067828A2 (en) 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
CN101389648B (zh) 2006-02-22 2013-07-17 默沙东公司 肽胃泌酸调节素衍生物
US20080305519A1 (en) 2006-02-23 2008-12-11 Qing Lin Biochemical method for specific protein labeling
KR20080113226A (ko) 2006-03-16 2008-12-29 더 스크립스 리서치 인스티튜트 비천연 아미노산 페닐셀레노시스테인을 함유하는 단백질의 유전자적으로 프로그램된 발현
KR20090005329A (ko) 2006-03-20 2009-01-13 머크 앤드 캄파니 인코포레이티드 뉴로메딘 ｕ 수용체 효능제 및 이의 용도
WO2007109354A2 (en) 2006-03-21 2007-09-27 Amylin Pharmaceuticals, Inc. Peptide-peptidase inhibitor conjugates and methods of using same
ES2495741T3 (es) 2006-04-20 2014-09-17 Amgen, Inc Compuestos de GLP-1
AU2007267833B2 (en) 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
WO2008028117A2 (en) 2006-08-31 2008-03-06 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
EP2069502B1 (en) 2006-09-27 2014-02-26 Novo Nordisk A/S Method for making maturated insulin polypeptides
KR20090091145A (ko) 2006-10-27 2009-08-26 웨이-치앙 션 지질화된 인터페론 및 이의 용도
US7981998B2 (en) 2006-12-14 2011-07-19 Aileron Therapeutics, Inc. Bis-sulfhydryl macrocyclization systems
CN105061577A (zh) 2006-12-14 2015-11-18 爱勒让治疗公司 双巯基大环化系统
AU2008216265B2 (en) 2007-02-15 2014-04-03 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
ES2398310T3 (es) 2007-02-23 2013-03-15 Aileron Therapeutics, Inc. Péptidos macrocíclicos unidos a triazol
US8420598B2 (en) 2007-04-20 2013-04-16 B & L Delipharm Corp. Mono modified exendin with polyethylene glycol or its derivatives and uses thereof
AU2008266753A1 (en) 2007-06-20 2008-12-24 Istituto Di Recerche Di Biologia Molecolare P. Angeletti S.P.A. ApoA-1 peptide mimetics
KR20100126361A (ko) 2008-02-08 2010-12-01 에일러론 테라퓨틱스 인코포레이티드 치료용 펩티드유사 거대고리
WO2009126292A2 (en) 2008-04-08 2009-10-15 Aileron Therapeutics, Inc. Biologically active peptidomimetic macrocycles
US20110144303A1 (en) 2008-04-08 2011-06-16 Aileron Therapeutics, Inc. Biologically Active Peptidomimetic Macrocycles
DK2300035T3 (en) 2008-06-17 2015-11-16 Univ Indiana Res & Tech Corp Mixed GIP-based agonists for the treatment of metabolic diseases and obesity
US8586707B2 (en) 2008-09-16 2013-11-19 The Research Foundation Of State University Of New York Stapled peptides and method of synthesis
ES2666458T3 (es) 2008-09-22 2018-05-04 Aileron Therapeutics, Inc. Macrociclos peptidomiméticos
CN102203126A (zh) 2008-09-22 2011-09-28 爱勒让治疗公司 用于制备纯化的多肽组合物的方法
CN102884074A (zh) 2008-09-22 2013-01-16 爱勒让治疗公司 拟肽大环化合物
EP2352507A4 (en) 2008-11-24 2012-04-25 Aileron Therapeutics Inc PEPTIDOMIMETIC MACROCYCLES WITH IMPROVED PROPERTIES
WO2010083347A2 (en) 2009-01-14 2010-07-22 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
WO2010096052A1 (en) 2009-02-19 2010-08-26 Merck Sharp & Dohme Corp. Oxyntomodulin analogs
AP3329A (en) 2009-07-13 2015-06-30 Zealand Pharma As Acylated glucagon analogues
MX2012003939A (es) 2009-09-30 2012-07-30 Glaxo Group Ltd Fusiones y conjugados de farmaco.
US20110223149A1 (en) 2009-10-14 2011-09-15 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
EP2512518A1 (en) 2009-12-16 2012-10-24 Novo Nordisk A/S Glp-1 receptor agonist compounds with a modified n-terminus
US8703701B2 (en) 2009-12-18 2014-04-22 Indiana University Research And Technology Corporation Glucagon/GLP-1 receptor co-agonists
US20110243943A1 (en) 2010-04-02 2011-10-06 Athena Discovery, Inc. Treatment using relaxin-fusion proteins with extended in vivo half-lives
JP2013532172A (ja) * 2010-07-09 2013-08-15 ダナ ファーバー キャンサー インスティテュート インコーポレイテッド 安定化したインスリン分泌促進ペプチド及び使用方法
BR112013000603A2 (pt) 2010-07-09 2016-07-05 Jv Bio Srl anticorpos conjugados com lipídios
WO2012012352A2 (en) 2010-07-19 2012-01-26 Amidebio, Llc Modified peptides and proteins
KR101382593B1 (ko) 2010-07-21 2014-04-10 한미사이언스 주식회사 신규한 지속형 글루카곤 결합체 및 이를 포함하는 비만 예방 및 치료용 약학적 조성물
MA34521B1 (fr) 2010-08-17 2013-09-02 Ambrx Inc Polypeptides de relaxine modifiés et leurs utilisations
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
US9029332B2 (en) 2010-12-15 2015-05-12 The Research Foundation For The State University Of New York Cross-linked peptides and proteins, methods of making same, and uses thereof
US8507428B2 (en) 2010-12-22 2013-08-13 Indiana University Research And Technology Corporation Glucagon analogs exhibiting GIP receptor activity
SG191252A1 (en) 2010-12-22 2013-07-31 Marcadia Biotech Inc Methods for treating metabolic disorders and obesity with gip and glp-1 receptor-active glucagon-based peptides
CA2834657A1 (en) 2011-04-29 2012-11-01 Kinemed, Inc. Chemical modification of apolipoprotein mimetic peptides for the production of therapeutic agents
EP2726502A1 (en) 2011-07-01 2014-05-07 Bayer Intellectual Property GmbH Relaxin fusion polypeptides and uses thereof
JP2014529293A (ja) 2011-07-08 2014-11-06 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングＢａｙｅｒ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ ＧｍｂＨ レラキシンを放出する融合タンパク質およびその使用
AR088392A1 (es) 2011-10-18 2014-05-28 Aileron Therapeutics Inc Macrociclos peptidomimeticos
KR101895047B1 (ko) 2011-12-30 2018-09-06 한미사이언스 주식회사 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
HK1205454A1 (en) 2012-02-15 2015-12-18 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
CN117462693A (zh) 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
US9254311B2 (en) 2012-04-02 2016-02-09 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins
US9273093B2 (en) 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
BR112015009470A2 (pt) 2012-11-01 2019-12-17 Aileron Therapeutics Inc aminoácidos dissubstituídos e seus métodos de preparação e uso
SG11201508469YA (en) * 2013-05-02 2015-11-27 Glaxosmithkline Ip Dev Ltd Therapeutic peptides
EP3019531A4 (en) 2013-07-11 2017-03-15 The California Institute for Biomedical Research Immunoglobulin fusion proteins and compositions thereof
CN105792851B (zh) * 2013-09-13 2023-10-10 斯克利普斯研究所 修饰的治疗剂及其组合物
US20180228907A1 (en) 2014-04-14 2018-08-16 Arvinas, Inc. Cereblon ligands and bifunctional compounds comprising the same
JO3575B1 (ar) 2015-01-09 2020-07-05 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
MA41794A (fr) 2015-03-18 2018-01-23 The California Institute For Biomedical Res Agents thérapeutiques modifiés et compositions associées
WO2017007612A1 (en) 2015-07-07 2017-01-12 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
WO2017024318A1 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Targeted protein degradation to attenuate adoptive t-cell therapy associated adverse inflammatory responses
WO2017024317A2 (en) 2015-08-06 2017-02-09 Dana-Farber Cancer Institute, Inc. Methods to induce targeted protein degradation through bifunctional molecules
US9809603B1 (en) 2015-08-18 2017-11-07 Deuterx, Llc Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
WO2017210600A1 (en) 2016-06-03 2017-12-07 The Scripps Research Institute Compositions and methods of modulating immune response
JOP20190095A1 (ar) * 2016-10-27 2019-04-28 Janssen Pharmaceutica Nv مركبات ببتيد تيروسين-تيروسين الحلقية كمعدلات لمستقبلات الببتيد العصبي y
CN117510491A (zh) 2016-12-23 2024-02-06 阿尔维纳斯运营股份有限公司 用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
EP3580212A4 (en) 2017-02-08 2021-03-17 Dana Farber Cancer Institute, Inc. REGULATION OF CHEMERIC ANTIGEN RECEPTORS
AU2018219292B2 (en) 2017-02-08 2024-09-26 Dana-Farber Cancer Institute, Inc. Tunable endogenous protein degradation with heterobifunctional compounds
AU2018248417A1 (en) 2017-04-05 2019-11-14 Revolution Medicines, Inc. Compounds that participate in cooperative binding and uses thereof
US11802132B2 (en) 2018-02-23 2023-10-31 Dana-Farber Cancer Institute, Inc. Small molecules for inducing selective protein degradation and uses thereof
WO2019203645A1 (en) * 2018-04-19 2019-10-24 Stichting Vu Protein macrocyclization
TWI847981B (zh) * 2018-04-25 2024-07-11 比利時商健生藥品公司 類升糖素肽1 (glp-1)融合肽偶合環狀酪酪肽接合物及其用途
CN112469731B (zh) 2018-07-23 2024-11-29 伊莱利利公司 Gip/glp1共激动剂化合物
EP3864030A4 (en) 2018-10-12 2022-09-21 The Scripps Research Institute Compounds and methods for dcaf-mediated protein degradation
AU2020397917A1 (en) * 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2017502024A (ja) 2013-12-18 2017-01-19 ザ カリフォルニア インスティテュート フォー バイオメディカル リサーチ 修飾された治療剤、ステープル留めされたペプチド脂質複合体、及びそれらの組成物
WO2016205488A1 (en) 2015-06-17 2016-12-22 The California Institute For Biomedical Research Modified therapeutic agents and compositions thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Yang, P-Y. et al.，Stapled, Long-Acting Glucagon-like Peptide 2 Analog with Efficacy in Dextran Sodium Sulfate Induced Mouse Colitis Models，J. Med. Chem.，2018年，vol.61，p.3218-3223

Also Published As

Publication number Publication date
CA3163522A1 (en) 2021-06-10
CN115052886B (zh) 2025-09-09
CA3163507A1 (en) 2021-06-10
WO2021113524A3 (en) 2021-07-15
JP7834640B2 (ja) 2026-03-24
EP4069274A4 (en) 2024-04-10
JP2023513658A (ja) 2023-04-03
US12583900B2 (en) 2026-03-24
AU2020397918A1 (en) 2022-06-23
EP4069726A2 (en) 2022-10-12
AU2020397917A1 (en) 2022-06-23
CN115052615A (zh) 2022-09-13
MX2022006861A (es) 2022-07-11
KR20220123648A (ko) 2022-09-08
CN115052886A (zh) 2022-09-13
EP4069274A1 (en) 2022-10-12
IL293460A (en) 2022-07-01
KR20220110244A (ko) 2022-08-05
EP4069726A4 (en) 2024-03-20
WO2021113535A1 (en) 2021-06-10
IL293522A (en) 2022-08-01
US20230057847A1 (en) 2023-02-23
MX2022006732A (es) 2022-08-19
WO2021113524A2 (en) 2021-06-10
US20230071371A1 (en) 2023-03-09
JP2023504184A (ja) 2023-02-01

Similar Documents

Publication Publication Date Title
JP7691421B2 (ja) Ｇｌｐ２受容体アゴニストおよびその使用方法
WO2022257979A1 (en) Long-acting dual gip/glp-1 peptide conjugates and methods of use
KR102455171B1 (ko) 변형된 치료제, 스테이플드 펩티드 지질 접합체, 및 이의 조성물
WO2016149501A2 (en) Modified therapeutic agents and compositions thereof
AU2014318579A1 (en) Modified therapeutic agents and compositions thereof
KR20170129841A (ko) 경구투여가 어려운 약물의 경구투여를 위한 신규한 약물 전달체 및 이의 제조방법
WO2025184552A2 (en) Dual gip/glp-1 peptide conjugates and methods of use
HK40097408A (en) Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
L. Lee et al. Synthesis of Glycolipid-based Drug Delivery Systems for Oral Administration
HK40037680A (en) Injectable solution at ph 7 comprising at least one basal insulin having a pi of between 5.8 and 8.5 and a copolyamino acid carrying carboxylate charges and hydrophobic radicals
CN111698999A (zh) 包含至少一种pi在5.8与8.5之间的基础胰岛素和带有羧酸根电荷及疏水基的共聚氨基酸的ph为7的可注射溶液
HK1228784A1 (en) Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof

Legal Events

Date Code Title Description
RD12 Notification of acceptance of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7432

Effective date: 20221208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221129

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221208

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231201

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20241105

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250204

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250404

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250514

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250530

R150 Certificate of patent or registration of utility model

Ref document number: 7691421

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150